BioFactura Announces Positive Results in Development of New Rapid Diagnostic Tests for Viral Hemorrhagic Fever Infections and Bioterrorism Threats
Posted on: Tuesday, 30 October 2007, 12:00 CDT
BioFactura, Inc., announced that the first test kits for viral hemorrhagic fever diagnosis have completed initial clinical testing in West Africa. The clinical test kits were developed under a $3.8M grant awarded by the National Institutes of Health (NIH) and were developed by BioFactura in collaboration with Tulane University, the US Army Medical Research Institute of Infectious Diseases (USAMRIID), Corgenix Medical Corp, Autoimmune Technologies, and partners in West Africa.
Under the NIH grant, Tulane is leading a three-year study designed to develop diagnostic tools for viral hemorrhagic fevers, some of which are caused by arenaviruses that are potential bioterrorism agents due to their high fatality rate and ease of transmission.
Luis Branco, Chief Scientific Officer of BioFactura, stated, "These significant achievements are the culmination of two years of highly productive collaboration within the Lassa Fever Consortium. The extensive panel of reagents constitutes a unique and highly valuable set of tools for the continuing development of multifaceted approaches to diagnose, prevent, and potentially treat viral hemorrhagic fevers."
Biosafety Level-4 studies related to this endeavor and subsequent field implementation of the diagnostic platform were performed by Joseph Fair, MPH, a predoctoral fellow at USAMRIID, under the supervision of Mary Guttieri, Ph.D., a USAMRIID Biodefense Research Microbiologist. According to USAMRIID Commander Colonel George W. Korch, Jr., initial field testing has been met with great success. "The recombinant protein diagnostic platform will permit the valuable and very necessary means by which to examine the prevalence of this deadly pathogen," Colonel Korch commented. "In addition to engineering effective and feasible diagnostic kits, this collaborative effort will provide an important gateway for future development of countermeasures to mitigate the threat of Lassa fever."
The clinical studies are being conducted through the Mano River Union Lassa Fever Network in Sierra Leone in conjunction with the World Health Organization and Tulane. "Clinical reports from Sierra Leone continue to show amazing results" said Robert Garry, Ph.D., Professor of Microbiology and Immunology at Tulane, and Principle Investigator of the NIH grant. "We believe this remarkable collaboration will result in diagnostic and detection products that will truly have a meaningful impact on healthcare in West Africa and fill a critical gap in bioterrorism defense."
Source: Business Wire
Related Articles
- Hutchinson Center to Build First U.S. Cancer Clinic and Training Facility in Africa Thanks, in Part, to a Grant From USAID
- New Medical Imaging Organization Launched to Represent Industry Personnel and Diagnostic Clinics
- MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
- Diagnostic HYBRIDS Receives Third Frontier Grant for Development of Assays to Monitor Drug Resistance and Vaccine Production
- Amarillo Diagnostic Clinic Selects Allscripts HealthMatics Office to Automate Clinical, Financial Operations
- 31 Free Clinics Share $1 Million in Grants From Blue Cross Blue Shield of Michigan and Blue Care Network
- Diagnostic Clinic Improves Patient Access and Saves Staff Time Through Secure Online Communications
- Cleveland Clinic Receives $13.5 Million Grant From the National Institutes of Health
- Emirates Diagnostic Clinic Adds Specialties and Services
- The Foundation for Innovative New Diagnostics (FIND) and Eiken Chemical Co. LTD. Announce Collaboration to Develop Rapid Diagnostic Test for Tuberculosis
 |
 |
User Comments (0)
RSS Feeds